Market Insights 310523
D K Jain
Dear Investor,
Markets always tend to be interesting with something or the other happening all the time. Our Morning Mantra is released before the opening bell and it includes the market commentary along with Corporate & Global news for the day.
US: Stocks on Wall Street closed mixed on Tuesday, pressured by worries about U.S. lawmakers opposed to a deal to raise the $31.4 trillion debt ceiling, but supported by another surge in Nvidia shares that briefly lifted the chipmaker into the rare club of companies valued at $1 trillion.
Dow | 33,043 | -51 | -0.2% |
Dow Futures | 33,008 | -81 | -0.2% |
Hangseng | 18,190 | -405 | -2.2% |
Nikkei | 30,977 | -352 | -1.1% |
SGX Nifty | 18,660 | -70 | -0.4% |
Asia: Asia-Pacific markets were mixed as Wall Street considered the likelihood of Congress passing a tentative deal on raising the U.S. debt ceiling amid growing opposition within the GOP.
Market is expected to open gap down and likely to witness profit booking during the day.
· Mahindra & Mahindra: The company incorporated subsidiary Mahindra Last Mile Mobility to manage its three-wheeler and small commercial vehicle business. The auto major also incorporated a step-down subsidiary Icarus Hybren to run the renewable energy production and distribution business.
· Aurobindo Pharma: The company received tentative new drug application approval from U.S. FDA for HIV drugs Dolutegravir, Entricitabine and Tenofovir Alafenamide tablets.
· Sun Pharmaceuticals Industries: The company received approval from China’s National Medical Products Administration for its new drug application of tildrakizumab injection used to treat moderate-to-severe plaque psoriasis.
· Lupin: The company entered a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, used in treatment of head and neck cancer.
Institutional Desk
•JK Cement Ltd.- BUY- 4QFY23 Result Update- Good set of numbers: JK Cement (JKCE) reported absolute EBITDA of Rs3.5bn (down 9% YoY), which was less than NBIE estimate of Rs3.8bn despite robust volume and realisation growth of 16% YoY and 2.1% YoY, respectively. This was due to higher expenditures towards Power & Fuel (up 48% YoY), raw materials (up 30% YoY) and Logistics (up 21% YoY). Lower clinker sales, higher trade sales (69.1% of total sales), of which premium products account for 10%, and better product mix (68.1% blended) contributed to increased profitability. In 4QFY23, margins were impacted by higher diesel prices, a busy season surcharge on rail freight and a Rail/Road mix of 16:84. The management indicated that the decline in international petcoke prices will result in a USD20 sequential decline in Power & Fuel costs over the next three quarters. JKCE has reduced its coal inventory from 5 months to 2 months, thereby relieving pressure on the company's working capital. The management sounded optimistic that the Panna facility will generate synergies - state subsidies, increase in market share to 8-10% in its primary markets and lower logistic costs, all of which will have a positive impact on the return ratios. We continue to have faith in the company's capabilities for strategic expansion, cost reduction, optimal utilization of new facilities and seizing opportunities as they arise. We value JKCE at 13x FY25E EV/EBITDA to arrive at our target price (TP) of Rs3,836.
•Jubilant Pharmova- ACCUMULATE- 4QFY23 Result Update- Decent performance; Consistency must for re-rating: Jubilant Pharmova’s 4QFY23 operational performance was better than NBIE expectations mainly due to strong growth in Radio Pharmacy and Allergy businesses. Excluding impairment charges of Rs1.7bn, net profit was in-line with NBIE estimate. Revenue grew by 9.9% YoY to Rs16.8bn. Strong growth in Radio Pharmacy and Allergy businesses was partially offset by a decline in Radio Pharma and CRDMO. Radio Pharma business declined by 4% YoY while the low-margin Radio Pharmacy business grew by 38.9% YoY. Allergy business grew by 31.8% YoY and Sterile CDMO business grew by 11.5% YoY. EBITDA margin improved by 367bps QoQ due to a sharp improvement in Radio Pharmacy and API margins. Excluding impairment charges, net profit stood at Rs722mn - almost in line with NBIE estimate of Rs735mn. For one or the other reasons, the company has consistently been disappointing on margins and profitability fronts. Hence, stability across businesses is must to re-rate the stock. We like the company’s Sterile CDMO, Radio Pharma and Allergy businesses (42% of overall revenue in FY23). But, low-margin and loss-making verticals like Generics, Radio Pharmacy and API (49% of overall sales in FY23) drag down the overall performance. However, we maintain our ACCUMULATE recommendation with a target price (TP) of Rs331 due to compelling valuation (trading at 10x FY25E EPS) and multiple drivers for improving margins and growth. Consistency in performance and improvement in overall product mix towards high-margin businesses are key to further re-rating.
•KNR Construction- BUY- 4QFY23 Result Update- Strong order book to drive growth: Despite revenue growth of 17% YoY in 4QFY23, KNR Construction (KNR) reported absolute EBIDTA of Rs2.1bn (up 3% YoY), which was less than NBIE estimate of Rs2.2bn. This was due to an increase in the cost of Raw Materials (up 34% YoY), the cost of Spreading & Assortment (up 29% YoY) and other expenses (up by 88% YoY). According to NBIE, the company's know-how and strong equipment base enable it to execute orders/projects more efficiently and at a lower cost. As of FY23, the order book totals Rs70.9bn, of which 50% is Roads (HAM), 22% is Irrigation, and 28% is Roads (others). The addition of Rs17.8bn in new orders brings the total order book to Rs88.7bn. The company intends to enter more business verticals in the disciplines of Elevated Metro Rail and Railway Projects Construction. We continue to like KNR due to the following factors: (1) Minimal leverage (2) Strong book-to-bill ratio (3x) and (3) Healthy dividend yield (4) Robust operating cash flow and (5) Well-managed working capital. We value the standalone business at 15x FY25E PAT and the asset business at 1x P/B on the basis of actual investments made.
•Natco Pharma- ACCUMULATE- 4QFY23 Result Update- Revlimid play resumes; base business outlook remains weak: Natco Pharma’s 4QFY23 results were way higher than NBIE estimates mainly on the back of higher-than-expected Revlimid sales. Revenue grew by 50.5% YoY to ~Rs9bn, mainly driven by robust sales in Export Formulations and APIs. Domestic Formulations business grew by 20.3% YoY on the back of CTPR launch in Crop Protection space and a low base. Owing to its presence in limited therapies and that too mainly through the institutional channel, the Natco Pharma management is keenly looking for inorganic opportunities to boost domestic growth. Crop Protection sales increased to Rs270mn as against Rs99mn in 3QFY23 on the back of a ramp up in CTPR sales. The expected market size of CTPR & Combination is ~Rs30bn. The company expects to garner 10-20% market share on the back of its early-mover advantage and inventory build-up. The Export Formulations business grew by 52.5% YoY to Rs7.1bn, driven by Revlimid. EBITDA margin stood at 37.8% vs NBIE estimate of 39.5%. The adjusted net profit grew by 113% YoY to Rs2.8bn. We remain cautious about Natco Pharma as growth is highly contingent on Revlimid and CTPR performance. Excluding these two, we do not see any near to medium term visibility in both US as well as Domestic market. Also, restructuring of the business to diversify into multiple geographies and segments as opposed to being a focused US-centric player is likely to weigh on base business margins in the short to medium term. The stock has given 17% return since the 3QFY23 results, factoring in all near-term opportunities. We maintain ACCUMULATE on Natco Pharma with a revised SOTP-based target price (TP) of Rs600, valuing it at 20x PE on FY25E base EPS of Rs19.4 and NPV of Rs212 for Revlimid and Imbruvica.
•Stove Kraft Limited- BUY- 4QFY23 Result Update- Margin pressure offsets industry outperforming topline growth: Stove Kraft Ltd (SKL) reported 4QFY23 revenue of Rs2.8bn, up 6.4% YoY (8.2% below NBIE Est.). Gross margin improved by 220bps YoY to 32.2%. EBITDA stood at Rs59mn, down 62% YoY. EBITDA margin contracted by 380bps YoY to 2.1%, way below NBIE estimate of 8.2%. SKL reported a net loss of Rs60mn vs PAT of Rs86mn in 4QFY22 due to higher interest costs (+54.1%). SKL reported at net loss of Rs60mn vs NBIE estimate of PAT of Rs113mn. The management highlighted that the demand weakness post Diwali continued in 4QFY23. However, SKL outperformed its peers as TTK Prestige/Hawkins Cooker/Butterfly Gandhimathi revenue declined by 12.7%/6.6%/1.6% YoY in 4QFY23. Even on full-year basis, SKL outperformed peers (revenue grew by 13% in FY23) as TTK Prestige/Hawkins Cooker/Butterfly Gandhimathi revenue improved by 3.7%/5%/6.1% in FY23. The management has maintained double-digit growth guidance for FY24 as it expects sales from the E-commerce channel to rebound post a muted performance in FY23 due to a high base. It further expects gross margin to improve on the back of softening RM costs and calibrated prices hikes across portfolio. The management expects EBITDA margin to reach 11% by 1HFY24-end as operating leverage kicks in (fixed costs are expected to remain at similar levels due to deferment of capex to 4QFY24/1QFY25). We expect SKL to reap the benefits of “value-for-money” brand positioning as affordable segment demand picks up due to softening of inflationary pressure. We continue to believe that SKL can outperform industry growth going forward, driven by distribution expansion, new product launches and exports. We expect margins to improve going ahead as operating leverage kicks in. We have marginally tweaked our numbers besides maintaining BUY with a target price (TP) of Rs535, valuing it at 17x PE on FY25E EPS.
•Suprajit Engineering- ACCUMULATE- 4QFY23 Result Update- Outlook for FY24 appears promising: Suprajit Engineering’s (SEL) consolidated revenue for 4QFY23 at ~Rs7bn was flattish QoQ. Gross margin stood at 44.1%, up 420bps YoY and 300bps QoQ. DCD performed strongly both in sales growth as well as margin on the back of a strong performance in OEM and Aftermarket segments. The PLD division reported EBITDA margin of 9% in 4QFY23 compared to 10.9% in 3QFY23, mainly driven by decline in the 2W segment. The management expects consolidated margin to improve in FY24. We believe that SEL will be one of the key beneficiaries of recovery in the domestic automotive industry with the company having a dominant market share in 2Ws (~75%) and 4Ws (~32%). Also, SEL has been consistently outperforming industry growth on the back of market share gains. Furthermore, SEL’s content per vehicle will rise with it gaining traction in new products like Instrument Cluster and other electronic products’ content rising by ~2x in 3-5 years. While the outlook for global business remains challenging, SEL derives comfort from a robust order pipeline to improve operational performance. SENA business division appears to be weak amid macro challenges in the US market, leading to lower volume for the customers. On the profitability front, we believe that the cost pass-through in LDC and PLD divisions remains a key variable. We believe that with the turnaround of LDC and PLD divisions and improving volume in SENA and DCD businesses, we will see further improvement in operating profit. Furthermore, SEL maintains a strong free cash flow (FCF) generating model with nominal capex requirements. We value SEL at 22x FY25E EPS to arrive at a target price (TP) of Rs425.
•Torrent Pharmaceuticals- BUY- 4QFY23 Result Update- Branded business growth remains intact: Torrent Pharma’s (Torrent) reported strong revenue growth in 4QFY23 with a beat against our estimate, largely led by continuous strong growth in Branded Generics markets and integration of the recently acquired Curatio portfolio while adjusted margin was in line with our expectation. Revenue grew by 16.9% YoY to Rs24.9bn (NBIE est.: Rs24.2bn) mainly on the back of robust growth in all the Branded Generics markets. The Domestic market grew by 21.6% YoY, aided by the Curatio acquisition and new launches in Chronic therapy. Excluding Curatio, domestic market growth stood at 15% YoY. Brazil market grew by 26.7% YoY to ~Rs3.2bn on the back of currency tailwinds, new launches and growth in the generics segment. Additionally, the German business continued to show signs of recovery, posting 16.1%/5% YoY/QoQ growth post the revival of the tender business. However, the US business continued to remain under pressure, declining by 2.9% QoQ to US$34mn due to pricing pressure and lack of new launches. EBITDA margin improved by 286bps YoY to 29.2% (29.6% ex inventory write-off). Adjusted net profit grew by 16.8% YoY to Rs2.9bn. The company is looking to repay majority of the debt of Curatio by FY24. We are positive about Torrent Pharma mainly due to its strong Chronic-centric branded portfolio, industry-leading PCPM in India and healthy margins & FCF, which continue to provide opportunity for further inorganic growth. We maintain BUY on Torrent Pharma with a target price (TP) of Rs1,981, valuing it at 18x FY25E EV/EBITDA.
Retail Desk
Time Technoplast Q4FY23 Concall Update
Outlook: Positive in long term
Revenue came at Rs. 1193 Cr (5.5% QoQ, 15% YoY)
• Established products (67% mix) grew 10% YoY
• VAP (Value Added Products) (33% mix) grew 26% YoY
• Co expects to grow by 15% in FY24. (Established: 10-12% & VAP: 25-30%)
• VAP mix for FY23 was at 23% and is expected to increase to increase to 30% in FY26 and to 35% in FY28.
• EBITDA Margin came at 14.2% vs QoQ 13.4%, YoY 13.3%
• EBITDA Margin will be at 15.5-16% once VAP mix reaches 35%.
• Co expects margins to improve by 20-30 bps each year.
• Total capex in FY23 was Rs. 223 Cr of which Rs. 137 Cr was towards VAP & Rs. 87 Cr was towards Established products.
• In FY22, co had a manufacturing capacity of 180 CNG Cascades (10,800 cylinders) annually. Co has increased the manufacturing capacity by 300 cascades (18,000 cylinders) in FY23 with a capital outlay of INR 55 Cr and will now further expand by 600 cascades (36,000 cylinders) in FY24 with a capex of Rs. 125 Cr. Total cascade manufacturing capacity will be 1,080 cascades (64,800 cylinders) per year from March 2024.
• By utilizing the full current capacity of 480 cascades, co can achieve peak revenue of Rs. 300 Cr. Once the full 1080 cascades come onboard, the peak revenue can be Rs. 800 Cr.
• Co has Rs. 260 Cr order book for CNG cascades.
• CNG cascade business is expected to have a revenue of Rs. 300 Cr in FY24 and is likely to scale up to Rs. 2k Cr over next 5 years.
• Co expects to make inroads in manufacture of hydrogen cylinders as well in future.
• Co has presence in 10 overseas countries and 3 continents which is leading to delays for the sale of the international business. As CY2022 got over recently, the due diligence will again happen in order to enhance the sale value. Co expects it to complete during H1FY24 from earlier deadline of Q1FY24.
• Co is also evaluating sale of businesses in 3 continents separately and has appointed 2 consultants for this.
• Considering the last several quarters of guidance and delivery, we believe there is a chance of further delays regarding the sale of international business.
• Co will use the sale proceeds to reduce debt by 50%, incur capex in composite cylinders and also give special dividend/buyback to reward shareholders.
• Total debt reduced by Rs. 15 Cr in FY23 from year ended FY22.
• Co intends to increase ROCE from current ~13% to ~20% by FY26 via higher growth in value added products, increase in margins, reduction in working capital and debt reduction upon sale of international business.
Stock is trading at P/E of 9.3x TTM EPS
Results Announced
V-Guard Industries Ltd. | CMP Rs. 246 | M Cap Rs. 10610 Cr | 52 W H/L 275/204 | § Result is above expectations § Revenue from Operations came at Rs. 1140.1 Cr (16.2% QoQ, 7.7% YoY) vs expectation of Rs. 1216.3 Cr, QoQ Rs. 980.8 Cr, YoY Rs. 1058.2 Cr § EBIDTA came at Rs. 98.6 Cr (49.7% QoQ, -11.2% YoY) vs expectation of Rs. 97.2 Cr, QoQ Rs. 65.9 Cr, YoY Rs. 111 Cr § EBITDA Margin came at 8.7% vs expectation of 8%, QoQ 6.7%, YoY 10.5% § Adj. PAT came at Rs. 72.8 Cr vs expectation of Rs. 62.3 Cr, QoQ Rs. 39.3 Cr, YoY Rs. 89.7 Cr § Quarter EPS is Rs. 1.7 § Stock is trading at P/E of 35.2x FY24E EPS |
Mazagon Dock Shipbuilders Ltd. | CMP Rs. 801 | M Cap Rs. 16164 Cr | 52 W H/L 937/229 | § Result is above expectations § Revenue from Operations came at Rs. 2078.6 Cr (14.5% QoQ, 48.9% YoY) vs expectation of Rs. 1798.6 Cr, QoQ Rs. 1815.9 Cr, YoY Rs. 1396.4 Cr § EBIDTA came at Rs. 210.6 Cr (-28.8% QoQ, 172.3% YoY) vs expectation of Rs. 121.1 Cr, QoQ Rs. 295.7 Cr, YoY Rs. 77.3 Cr § EBITDA Margin came at 10.1% vs expectation of 6.7%, QoQ 16.3%, YoY 5.5% § Adj. PAT came at Rs. 296.8 Cr vs expectation of Rs. 211.1 Cr, QoQ Rs. 337.3 Cr, YoY Rs. 144.9 Cr § Quarter EPS is Rs. 14.7 § Stock is trading at P/E of 12.4x FY24E EPS |
Ador Welding Ltd. | CMP Rs. 1208 | M Cap Rs. 1642 Cr | 52 W H/L 1271/590 | § Result is above expectations § Revenue from Operations came at Rs. 235.5 Cr (18.6% QoQ, 17.9% YoY) vs expectation of Rs. 225 Cr, QoQ Rs. 198.5 Cr, YoY Rs. 199.8 Cr § EBIDTA came at Rs. 31.8 Cr (32.3% QoQ, 79.9% YoY) vs expectation of Rs. 21.8 Cr, QoQ Rs. 24 Cr, YoY Rs. 17.7 Cr § EBITDA Margin came at 13.5% vs expectation of 9.7%, QoQ 12.1%, YoY 8.8% § Adj. PAT came at Rs. 21.9 Cr vs expectation of Rs. 23.4 Cr, QoQ Rs. 16.6 Cr, YoY Rs. 11.5 Cr § Quarter EPS is Rs. 16.1 § Stock is trading at P/E of 22.6x FY24E EPS |
3M India Ltd. | CMP Rs. 24324 | M Cap Rs. 27401 Cr | 52 W H/L 25240/18900 | § Result has improved § Revenue from Operations came at Rs. 1046 Cr (5.3% QoQ, 13% YoY) vs QoQ Rs. 993 Cr, YoY Rs. 925.6 Cr § EBIDTA came at Rs. 194.3 Cr (13.9% QoQ, 23.4% YoY) vs QoQ Rs. 170.6 Cr, YoY Rs. 157.5 Cr § EBITDA Margin came at 18.6% vs QoQ 17.2%, YoY 17% § Adj. PAT came at Rs. 135.7 Cr vs QoQ Rs. 124.8 Cr, YoY Rs. 110.9 Cr § Quarter EPS is Rs. 120.5 § Stock is trading at P/E of 60.8x TTM EPS |
Marksans Pharma Ltd. | CMP Rs. 78 | M Cap Rs. 3522 Cr | 52 W H/L 83/39 | § Result has improved § Revenue from Operations came at Rs. 486 Cr (1.3% QoQ, 16.3% YoY) vs QoQ Rs. 479.8 Cr, YoY Rs. 418 Cr § EBIDTA came at Rs. 88.1 Cr (14.9% QoQ, 38.4% YoY) vs QoQ Rs. 76.6 Cr, YoY Rs. 63.6 Cr § EBITDA Margin came at 18.1% vs QoQ 16%, YoY 15.2% § Adj. PAT came at Rs. 81.9 Cr vs QoQ Rs. 63.4 Cr, YoY Rs. 29.7 Cr § Quarter EPS is Rs. 1.8 § Stock is trading at P/E of 13.2x TTM EPS |
Arvind Fashions Ltd. | CMP Rs. 270 | M Cap Rs. 3585 Cr | 52 W H/L 389/233 | § Result has improved § Revenue from Operations came at Rs. 1140 Cr (-3.3% QoQ, 24.4% YoY) vs QoQ Rs. 1178.9 Cr, YoY Rs. 916.7 Cr § EBIDTA came at Rs. 124 Cr (2.8% QoQ, 69.8% YoY) vs QoQ Rs. 120.6 Cr, YoY Rs. 73.1 Cr § EBITDA Margin came at 10.9% vs QoQ 10.2%, YoY 8% § Adj. PAT came at Rs. 10.9 Cr vs QoQ Rs. 8.1 Cr, YoY Rs. 0.8 Cr § Quarter EPS is Rs. 0.8 § Stock is trading at P/E of 25.2x FY24E EPS |
Mawana Sugars Ltd. | CMP Rs. 98 | M Cap Rs. 385 Cr | 52 W H/L 127/75 | § Result has improved § Revenue from Operations came at Rs. 350.3 Cr (-27.3% QoQ, 19.1% YoY) vs QoQ Rs. 481.8 Cr, YoY Rs. 294.1 Cr § EBIDTA came at Rs. 81.3 Cr (315.8% QoQ, 31.4% YoY) vs QoQ Rs. 19.5 Cr, YoY Rs. 61.9 Cr § EBITDA Margin came at 23.2% vs QoQ 4.1%, YoY 21% § Adj. PAT came at Rs. 52.1 Cr vs QoQ Rs. 5.2 Cr, YoY Rs. 35 Cr § Quarter EPS is Rs. 13.3 § Stock is trading at P/E of 27.6x TTM EPS |
Fiem Industries Ltd. | CMP Rs. 1832 | M Cap Rs. 2411 Cr | 52 W H/L 2087/839 | § Result has improved § Revenue from Operations came at Rs. 436.2 Cr (-1.3% QoQ, -10.9% YoY) vs QoQ Rs. 442.1 Cr, YoY Rs. 489.5 Cr § EBIDTA came at Rs. 60.5 Cr (1.3% QoQ, -6.7% YoY) vs QoQ Rs. 59.7 Cr, YoY Rs. 64.8 Cr § EBITDA Margin came at 13.9% vs QoQ 13.5%, YoY 13.2% § Adj. PAT came at Rs. 38.1 Cr vs QoQ Rs. 31.9 Cr, YoY Rs. 33.7 Cr § Quarter EPS is Rs. 28.9 § Stock is trading at P/E of 14.1x FY24E EPS |
Indian Metals & Ferro Alloys Ltd. | CMP Rs. 284 | M Cap Rs. 1534 Cr | 52 W H/L 382/221 | § Result has improved § Revenue from Operations came at Rs. 636.9 Cr (2.1% QoQ, -15.8% YoY) vs QoQ Rs. 623.6 Cr, YoY Rs. 756.7 Cr § EBIDTA came at Rs. 136.5 Cr (122.8% QoQ, -28.4% YoY) vs QoQ Rs. 61.2 Cr, YoY Rs. 190.5 Cr § EBITDA Margin came at 21.4% vs QoQ 9.8%, YoY 25.2% § Adj. PAT came at Rs. 69.9 Cr vs QoQ Rs. 19.9 Cr, YoY Rs. 142.6 Cr § Quarter EPS is Rs. 12.9 § Stock is trading at P/E of 6.4x TTM EPS |
Astrazeneca Pharma India Ltd. | CMP Rs. 3332 | M Cap Rs. 8330 Cr | 52 W H/L 3620/2520 | § Result has improved § Revenue from Operations came at Rs. 284.7 Cr (14% QoQ, 22.7% YoY) vs QoQ Rs. 249.8 Cr, YoY Rs. 232 Cr § EBIDTA came at Rs. 59.8 Cr (63.6% QoQ, 57.7% YoY) vs QoQ Rs. 36.6 Cr, YoY Rs. 38 Cr § EBITDA Margin came at 21% vs QoQ 14.6%, YoY 16.4% § Adj. PAT came at Rs. 57.5 Cr vs QoQ Rs. 29.3 Cr, YoY Rs. 28 Cr § Quarter EPS is Rs. 23 § Stock is trading at P/E of 59.7x TTM EPS |
Landmark Cars Ltd. | CMP Rs. 712 | M Cap Rs. 2821 Cr | 52 W H/L 718/431 | § Result has improved § Revenue from Operations came at Rs. 853.8 Cr (-2.5% QoQ, 17.5% YoY) vs QoQ Rs. 876.1 Cr, YoY Rs. 726.6 Cr § EBIDTA came at Rs. 60.8 Cr (-6.4% QoQ, 16.6% YoY) vs QoQ Rs. 64.9 Cr, YoY Rs. 52.1 Cr § EBITDA Margin came at 7.1% vs QoQ 7.4%, YoY 7.2% § Adj. PAT came at Rs. 24.1 Cr vs QoQ Rs. 32.2 Cr, YoY Rs. 18.8 Cr § Quarter EPS is Rs. 6.1 § Stock is trading at P/E of 32.8x TTM EPS |
Tega Industries Ltd. | CMP Rs. 682 | M Cap Rs. 4526 Cr | 52 W H/L 726/405 | § Result has improved § Revenue from Operations came at Rs. 396.4 Cr (33.5% QoQ, 36.7% YoY) vs QoQ Rs. 296.9 Cr, YoY Rs. 290.1 Cr § EBIDTA came at Rs. 102.8 Cr (52.8% QoQ, 49.1% YoY) vs QoQ Rs. 67.3 Cr, YoY Rs. 69 Cr § EBITDA Margin came at 25.9% vs QoQ 22.7%, YoY 23.8% § Adj. PAT came at Rs. 77.3 Cr vs QoQ Rs. 48.4 Cr, YoY Rs. 48.9 Cr § Quarter EPS is Rs. 11.6 § Stock is trading at P/E of 23.7x FY24E EPS |
Welspun Corp Ltd. | CMP Rs. 243 | M Cap Rs. 6366 Cr | 52 W H/L 299/178 | § Result has improved § Revenue from Operations came at Rs. 4070.2 Cr (69.4% QoQ, 102.4% YoY) vs QoQ Rs. 2402.3 Cr, YoY Rs. 2011.1 Cr § EBIDTA came at Rs. 420.6 Cr (152.8% QoQ, 490.6% YoY) vs QoQ Rs. 166.4 Cr, YoY Rs. 71.2 Cr § EBITDA Margin came at 10.3% vs QoQ 6.9%, YoY 3.5% § Adj. PAT came at Rs. 235.9 Cr vs QoQ Rs. 23.2 Cr, YoY Rs. 236.2 Cr § Quarter EPS is Rs. 9 § Stock is trading at P/E of 8.4x FY24E EPS |
Arman Financial Services Ltd. - C | CMP Rs. 1581 | M Cap Rs. 1343 Cr | 52 W H/L 1706/894 | § Result has improved § NII came at Rs. 65.2 Cr vs YoY Rs. 41.9 Cr, QoQ Rs. 47.9 Cr § PBP came at Rs. 62.8 Cr vs YoY Rs. 32.8 Cr, QoQ Rs. 38.6 Cr § Provision came at Rs. 14 Cr vs YoY Rs. 10.7 Cr, QoQ Rs. 9.2 Cr § PAT came at Rs. 36.2 Cr vs YoY Rs. 16.3 Cr, QoQ Rs. 22 Cr § # Asset quality and loan book metrics are awaited § Stock is trading at 3.7x trailing P/BV |
Rana Sugars Ltd. | CMP Rs. 23 | M Cap Rs. 353 Cr | 52 W H/L 32/19 | § Result has improved § Revenue from Operations came at Rs. 451.6 Cr (21.9% QoQ, -7.1% YoY) vs QoQ Rs. 370.4 Cr, YoY Rs. 486.1 Cr § EBIDTA came at Rs. 57.5 Cr (132.4% QoQ, -6.5% YoY) vs QoQ Rs. 24.8 Cr, YoY Rs. 61.5 Cr § EBITDA Margin came at 12.7% vs QoQ 6.7%, YoY 12.7% § Adj. PAT came at Rs. 45.4 Cr vs QoQ Rs. 1.6 Cr, YoY Rs. 16.6 Cr § Quarter EPS is Rs. 3 § Stock is trading at P/E of 5.6x TTM EPS |
Indo Count Industries Ltd. | CMP Rs. 157 | M Cap Rs. 3109 Cr | 52 W H/L 170/101 | § Result has improved § Revenue from Operations came at Rs. 807.1 Cr (21.9% QoQ, 16.9% YoY) vs QoQ Rs. 662.1 Cr, YoY Rs. 690.3 Cr § EBIDTA came at Rs. 144.2 Cr (84.6% QoQ, 9.1% YoY) vs QoQ Rs. 78.1 Cr, YoY Rs. 132.2 Cr § EBITDA Margin came at 17.9% vs QoQ 11.8%, YoY 19.1% § Adj. PAT came at Rs. 94.7 Cr vs QoQ Rs. 37.7 Cr, YoY Rs. 85.2 Cr § Quarter EPS is Rs. 4.8 § Stock is trading at P/E of 9.7x FY24E EPS |
Himatsingka Seide Ltd. | CMP Rs. 86 | M Cap Rs. 847 Cr | 52 W H/L 136/68 | § Result has improved § Revenue from Operations came at Rs. 689.7 Cr (-6.4% QoQ, -9.8% YoY) vs QoQ Rs. 736.8 Cr, YoY Rs. 764.8 Cr § EBIDTA came at Rs. 122.1 Cr (17.6% QoQ, 21.5% YoY) vs QoQ Rs. 103.8 Cr, YoY Rs. 100.4 Cr § EBITDA Margin came at 17.7% vs QoQ 14.1%, YoY 13.1% § Adj. PAT came at Rs. 22.4 Cr vs QoQ Rs. 2.2 Cr, YoY Rs. 8 Cr § Quarter EPS is Rs. 2.3 § Stock is trading at P/E of 9.7x FY24E EPS |
PTC Industries Ltd. | CMP Rs. 2470 | M Cap Rs. 3305 Cr | 52 W H/L 3080/1303 | § Result has improved § Revenue from Operations came at Rs. 62.2 Cr (9.3% QoQ, 22.7% YoY) vs QoQ Rs. 56.9 Cr, YoY Rs. 50.7 Cr § EBIDTA came at Rs. 18.5 Cr (51.8% QoQ, 55.4% YoY) vs QoQ Rs. 12.2 Cr, YoY Rs. 11.9 Cr § EBITDA Margin came at 29.7% vs QoQ 21.4%, YoY 23.5% § Adj. PAT came at Rs. 9.2 Cr vs QoQ Rs. 6.1 Cr, YoY Rs. 4.6 Cr § Quarter EPS is Rs. 6.9 § Stock is trading at P/E of 128.1x TTM EPS |
Action Construction Equipment Ltd. | CMP Rs. 453 | M Cap Rs. 5397 Cr | 52 W H/L 470/193 | § Result has improved § Revenue from Operations came at Rs. 613.8 Cr (10.3% QoQ, 20.2% YoY) vs QoQ Rs. 556.3 Cr, YoY Rs. 510.6 Cr § EBIDTA came at Rs. 73.3 Cr (18.5% QoQ, 55.2% YoY) vs QoQ Rs. 61.9 Cr, YoY Rs. 47.2 Cr § EBITDA Margin came at 11.9% vs QoQ 11.1%, YoY 9.2% § Adj. PAT came at Rs. 47.7 Cr vs QoQ Rs. 46.5 Cr, YoY Rs. 35.4 Cr § Quarter EPS is Rs. 4 § Stock is trading at P/E of 31.4x TTM EPS |
Torrent Pharmaceuticals Ltd. | CMP Rs. 1717 | M Cap Rs. 58114 Cr | 52 W H/L 1750/1260 | § Result is in-line with expectations § Revenue from Operations came at Rs. 2491 Cr (0% QoQ, 16.9% YoY) vs expectation of Rs. 2481.4 Cr, QoQ Rs. 2491 Cr, YoY Rs. 2131 Cr § EBIDTA came at Rs. 727 Cr (0.4% QoQ, 29.6% YoY) vs expectation of Rs. 728.6 Cr, QoQ Rs. 724 Cr, YoY Rs. 561 Cr § EBITDA Margin came at 29.2% vs expectation of 29.4%, QoQ 29.1%, YoY 26.3% § Adj. PAT came at Rs. 287 Cr vs expectation of Rs. 320.3 Cr, QoQ Rs. 283 Cr, YoY Rs. 367 Cr § Quarter EPS is Rs. 8.5 § Stock is trading at P/E of 36.2x FY24E EPS |
Lemon Tree Hotels Ltd. | CMP Rs. 96 | M Cap Rs. 7606 Cr | 52 W H/L 103/52 | § Result is in-line with expectations § Revenue from Operations came at Rs. 252.7 Cr (8.2% QoQ, 111.4% YoY) vs expectation of Rs. 250.3 Cr, QoQ Rs. 233.5 Cr, YoY Rs. 119.5 Cr § EBIDTA came at Rs. 139.9 Cr (10.6% QoQ, 548% YoY) vs expectation of Rs. 137.8 Cr, QoQ Rs. 126.5 Cr, YoY Rs. 21.6 Cr § EBITDA Margin came at 55.4% vs expectation of 55%, QoQ 54.2%, YoY 18.1% § Adj. PAT came at Rs. 44 Cr vs expectation of Rs. 47.6 Cr, QoQ Rs. 40 Cr, YoY Rs. -24.6 Cr § Quarter EPS is Rs. 0.6 § Stock is trading at P/E of 48.8x FY24E EPS |
Aegis Logistics Ltd. | CMP Rs. 369 | M Cap Rs. 12952 Cr | 52 W H/L 411/193 | § Result is broadly in-line with expectations § Revenue from Operations came at Rs. 2154.5 Cr (3.2% QoQ, 2.4% YoY) vs expectation of Rs. 2238 Cr, QoQ Rs. 2086.7 Cr, YoY Rs. 2103.6 Cr § EBIDTA came at Rs. 202.6 Cr (-6.3% QoQ, 41.6% YoY) vs expectation of Rs. 223.1 Cr, QoQ Rs. 216.1 Cr, YoY Rs. 143.1 Cr § EBITDA Margin came at 9.4% vs expectation of 10%, QoQ 10.4%, YoY 6.8% § Adj. PAT came at Rs. 140.9 Cr vs expectation of Rs. 132.6 Cr, QoQ Rs. 125.3 Cr, YoY Rs. 94.8 Cr § Quarter EPS is Rs. 4 § Stock is trading at P/E of 24.4x FY24E EPS |
Apollo Hospitals Enterprise Ltd. | CMP Rs. 4719 | M Cap Rs. 67856 Cr | 52 W H/L 4902/3362 | § Result is below expectations § Revenue from Operations came at Rs. 4302.2 Cr (0.9% QoQ, 21.3% YoY) vs expectation of Rs. 4316.2 Cr, QoQ Rs. 4263.6 Cr, YoY Rs. 3546.4 Cr § EBIDTA came at Rs. 488.2 Cr (-3.4% QoQ, 5.4% YoY) vs expectation of Rs. 510.8 Cr, QoQ Rs. 505.4 Cr, YoY Rs. 463.2 Cr § EBITDA Margin came at 11.3% vs expectation of 11.8%, QoQ 11.9%, YoY 13.1% § Adj. PAT came at Rs. 145.6 Cr vs expectation of Rs. 202.5 Cr, QoQ Rs. 153.5 Cr, YoY Rs. 90.1 Cr § Quarter EPS is Rs. 10.1 § Stock is trading at P/E of 55.8x FY24E EPS |
Lumax Auto Technologies Ltd. | CMP Rs. 331 | M Cap Rs. 2256 Cr | 52 W H/L 342/152 | § Result is below expectations § Revenue from Operations came at Rs. 303.2 Cr (-8.4% QoQ, -4.4% YoY) vs expectation of Rs. 462.6 Cr, QoQ Rs. 331 Cr, YoY Rs. 317.1 Cr § EBIDTA came at Rs. 26.1 Cr (0.8% QoQ, 11.5% YoY) vs expectation of Rs. 48.5 Cr, QoQ Rs. 25.9 Cr, YoY Rs. 23.4 Cr § EBITDA Margin came at 8.6% vs expectation of 10.5%, QoQ 7.8%, YoY 7.4% § Adj. PAT came at Rs. 21.9 Cr vs expectation of Rs. 23.4 Cr, QoQ Rs. 17.5 Cr, YoY Rs. 14.9 Cr § Quarter EPS is Rs. 3.2 § Stock is trading at P/E of 18.8x FY24E EPS |
Sunflag Iron And Steel Company Ltd. | CMP Rs. 164 | M Cap Rs. 2958 Cr | 52 W H/L 176/72 | § Result has declined § Revenue from Operations came at Rs. 837 Cr (-3.7% QoQ, 29% YoY) vs QoQ Rs. 869.4 Cr, YoY Rs. 649 Cr § EBIDTA came at Rs. 97.2 Cr (-16.7% QoQ, 23.6% YoY) vs QoQ Rs. 116.6 Cr, YoY Rs. 78.6 Cr § EBITDA Margin came at 11.6% vs QoQ 13.4%, YoY 12.1% § Adj. PAT came at Rs. 39.7 Cr vs QoQ Rs. 59.7 Cr, YoY Rs. 40.8 Cr § Quarter EPS is Rs. 2.2 § Stock is trading at P/E of -38.1x TTM EPS |
Heranba Industries Ltd. | CMP Rs. 331 | M Cap Rs. 1325 Cr | 52 W H/L 621/265 | § Result has declined § Revenue from Operations came at Rs. 258.9 Cr (-7.6% QoQ, -26.1% YoY) vs QoQ Rs. 280.2 Cr, YoY Rs. 350.1 Cr § EBIDTA came at Rs. 22.8 Cr (-11% QoQ, -63.6% YoY) vs QoQ Rs. 25.6 Cr, YoY Rs. 62.5 Cr § EBITDA Margin came at 8.8% vs QoQ 9.1%, YoY 17.9% § Adj. PAT came at Rs. 14.3 Cr vs QoQ Rs. 14.4 Cr, YoY Rs. 42.6 Cr § Quarter EPS is Rs. 3.6 § Stock is trading at P/E of 12x TTM EPS |
Lux Industries Ltd. | CMP Rs. 1455 | M Cap Rs. 4374 Cr | 52 W H/L 2218/1123 | § Result has declined § Revenue from Operations came at Rs. 715.2 Cr (55.8% QoQ, 21.9% YoY) vs QoQ Rs. 459.1 Cr, YoY Rs. 586.9 Cr § EBIDTA came at Rs. 42.2 Cr (29.7% QoQ, -60.6% YoY) vs QoQ Rs. 32.5 Cr, YoY Rs. 107 Cr § EBITDA Margin came at 5.9% vs QoQ 7.1%, YoY 18.2% § Adj. PAT came at Rs. 31.2 Cr vs QoQ Rs. 18.1 Cr, YoY Rs. 73.8 Cr § Quarter EPS is Rs. 10.4 § Stock is trading at P/E of 30.8x TTM EPS |
Dollar Industries Ltd. | CMP Rs. 359 | M Cap Rs. 2036 Cr | 52 W H/L 553/310 | § Result has declined § Revenue from Operations came at Rs. 406.4 Cr (42.4% QoQ, 8.9% YoY) vs QoQ Rs. 285.3 Cr, YoY Rs. 373 Cr § EBIDTA came at Rs. 11.3 Cr (-41.9% QoQ, -79.6% YoY) vs QoQ Rs. 19.4 Cr, YoY Rs. 55.4 Cr § EBITDA Margin came at 2.8% vs QoQ 6.8%, YoY 14.8% § Adj. PAT came at Rs. 0.5 Cr vs QoQ Rs. 7.7 Cr, YoY Rs. 36.4 Cr § Quarter EPS is Rs. 0.1 § Stock is trading at P/E of 15.6x FY24E EPS |
Elin Electronics Ltd. | CMP Rs. 140 | M Cap Rs. 695 Cr | 52 W H/L 140 | § Result has declined § Revenue from Operations came at Rs. 268.7 Cr (32.9% QoQ, -15.2% YoY) vs QoQ Rs. 202.2 Cr, YoY Rs. 317 Cr § EBIDTA came at Rs. 8.8 Cr (-33% QoQ, -64.8% YoY) vs QoQ Rs. 13.2 Cr, YoY Rs. 25.1 Cr § EBITDA Margin came at 3.3% vs QoQ 6.5%, YoY 7.9% § Adj. PAT came at Rs. 1.6 Cr vs QoQ Rs. 4.6 Cr, YoY Rs. 12.9 Cr § Quarter EPS is Rs. 0.3 § Stock is trading at P/E of 112.4x TTM EPS |
KRBL Ltd. | CMP Rs. 404 | M Cap Rs. 9498 Cr | 52 W H/L 449/198 | § Result has declined § Revenue from Operations came at Rs. 1279.7 Cr (-16.7% QoQ, 29.6% YoY) vs QoQ Rs. 1536 Cr, YoY Rs. 987.4 Cr § EBIDTA came at Rs. 143.9 Cr (-48.4% QoQ, -11.5% YoY) vs QoQ Rs. 278.8 Cr, YoY Rs. 162.5 Cr § EBITDA Margin came at 11.2% vs QoQ 18.2%, YoY 16.5% § Adj. PAT came at Rs. 118 Cr vs QoQ Rs. 205.5 Cr, YoY Rs. 109.1 Cr § Quarter EPS is Rs. 5 § Stock is trading at P/E of 13.5x TTM EPS |
Graphite India Ltd. | CMP Rs. 321 | M Cap Rs. 6272 Cr | 52 W H/L 467/252 | § Result has declined § Revenue from Operations came at Rs. 815 Cr (16.3% QoQ, -3.4% YoY) vs QoQ Rs. 701 Cr, YoY Rs. 844 Cr § EBIDTA came at Rs. 62 Cr (-13.9% QoQ, -29.5% YoY) vs QoQ Rs. 72 Cr, YoY Rs. 88 Cr § EBITDA Margin came at 7.6% vs QoQ 10.3%, YoY 10.4% § Adj. PAT came at Rs. 29 Cr vs QoQ Rs. 61 Cr, YoY Rs. 95 Cr § Quarter EPS is Rs. 1.5 § Stock is trading at P/E of 10.5x FY24E EPS |
Reliance Infrastructure Ltd. | CMP Rs. 139 | M Cap Rs. 4890 Cr | 52 W H/L 201/81 | § Result has declined § Revenue from Operations came at Rs. 4159.3 Cr (1.8% QoQ, 0% YoY) vs QoQ Rs. 4085.8 Cr, YoY Rs. 4159.8 Cr § EBIDTA came at Rs. 780.7 Cr (-5.8% QoQ, 618.9% YoY) vs QoQ Rs. 829 Cr, YoY Rs. 108.6 Cr § EBITDA Margin came at 18.8% vs QoQ 20.3%, YoY 2.6% § Adj. PAT came at Rs. -313.3 Cr vs QoQ Rs. -267.5 Cr, YoY Rs. -449.1 Cr § Quarter EPS is Rs. -8.9 § Stock is trading at P/E of -6x TTM EPS |
Kitex Garments Ltd. | CMP Rs. 163 | M Cap Rs. 1084 Cr | 52 W H/L 274/136 | § Result is weak § Revenue from Operations came at Rs. 97.7 Cr (43.2% QoQ, -61.5% YoY) vs QoQ Rs. 68.2 Cr, YoY Rs. 253.6 Cr § EBIDTA came at Rs. -6.5 Cr (322.3% QoQ, -111.8% YoY) vs QoQ Rs. -1.5 Cr, YoY Rs. 55.2 Cr § EBITDA Margin came at -6.6% vs QoQ -2.3%, YoY 21.8% § Adj. PAT came at Rs. 3.4 Cr vs QoQ Rs. -4.1 Cr, YoY Rs. 44.2 Cr § Quarter EPS is Rs. 0.5 § Stock is trading at P/E of 18.8x TTM EPS |
Bharat Rasayan Ltd. | CMP Rs. 10269 | M Cap Rs. 4267 Cr | 52 W H/L 13150/8299 | § Result has declined § Revenue from Operations came at Rs. 305.9 Cr (-1.1% QoQ, -31.2% YoY) vs QoQ Rs. 309.3 Cr, YoY Rs. 444.8 Cr § EBIDTA came at Rs. 54.7 Cr (5.7% QoQ, -36.2% YoY) vs QoQ Rs. 51.7 Cr, YoY Rs. 85.7 Cr § EBITDA Margin came at 17.9% vs QoQ 16.7%, YoY 19.3% § Adj. PAT came at Rs. 30.3 Cr vs QoQ Rs. 34.1 Cr, YoY Rs. 64.6 Cr § Quarter EPS is Rs. 72.8 § Stock is trading at P/E of 33.6x TTM EPS |
Fairchem Organics Ltd. | CMP Rs. 1160 | M Cap Rs. 1510 Cr | 52 W H/L 2450/905 | § Result has improved § Revenue from Operations came at Rs. 151.5 Cr (47.8% QoQ, -14.7% YoY) vs QoQ Rs. 102.5 Cr, YoY Rs. 177.6 Cr § EBIDTA came at Rs. 16.6 Cr (351.8% QoQ, -11.3% YoY) vs QoQ Rs. 3.7 Cr, YoY Rs. 18.7 Cr § EBITDA Margin came at 11% vs QoQ 3.6%, YoY 10.5% § Adj. PAT came at Rs. 11.9 Cr vs QoQ Rs. 0.6 Cr, YoY Rs. 11.2 Cr § Quarter EPS is Rs. 9.1 § Stock is trading at P/E of 34.7x TTM EPS |
India Pesticides Ltd. | CMP Rs. 220 | M Cap Rs. 2536 Cr | 52 W H/L 330/197 | § Result has declined § Revenue from Operations came at Rs. 198.2 Cr (-8.9% QoQ, 11.8% YoY) vs QoQ Rs. 217.6 Cr, YoY Rs. 177.3 Cr § EBIDTA came at Rs. 42.1 Cr (-9.5% QoQ, -0.9% YoY) vs QoQ Rs. 46.5 Cr, YoY Rs. 42.5 Cr § EBITDA Margin came at 21.3% vs QoQ 21.4%, YoY 24% § Adj. PAT came at Rs. 30 Cr vs QoQ Rs. 34.8 Cr, YoY Rs. 30.7 Cr § Quarter EPS is Rs. 2.6 § Stock is trading at P/E of 17.7x TTM EPS |
Patanjali Foods Ltd. | CMP Rs. 946 | M Cap Rs. 34227 Cr | 52 W H/L 1495/852 | § Result has declined § Revenue from Operations came at Rs. 7872.9 Cr (-0.7% QoQ, 18.1% YoY) vs QoQ Rs. 7926.6 Cr, YoY Rs. 6663.7 Cr § EBIDTA came at Rs. 326.3 Cr (-11.3% QoQ, -19.6% YoY) vs QoQ Rs. 368 Cr, YoY Rs. 406.1 Cr § EBITDA Margin came at 4.1% vs QoQ 4.6%, YoY 6.1% § Adj. PAT came at Rs. 263.7 Cr vs QoQ Rs. 269.2 Cr, YoY Rs. 234.4 Cr § Quarter EPS is Rs. 7.3 § Stock is trading at P/E of 19.8x FY24E EPS |
Rashtriya Chemicals and Fertilizers Ltd. | CMP Rs. 102 | M Cap Rs. 5613 Cr | 52 W H/L 145/71 | § Result has declined § Revenue from Operations came at Rs. 4683.9 Cr (-24.9% QoQ, 14% YoY) vs QoQ Rs. 6235.1 Cr, YoY Rs. 4109.9 Cr § EBIDTA came at Rs. 196.6 Cr (-55.1% QoQ, -42.8% YoY) vs QoQ Rs. 438.3 Cr, YoY Rs. 343.5 Cr § EBITDA Margin came at 4.2% vs QoQ 7%, YoY 8.4% § Adj. PAT came at Rs. 159.6 Cr vs QoQ Rs. 245.2 Cr, YoY Rs. 212 Cr § Quarter EPS is Rs. 2.9 § Stock is trading at P/E of 5.8x TTM EPS |
Gujarat Mineral Development Corporation Ltd. | CMP Rs. 163 | M Cap Rs. 5196 Cr | 52 W H/L 187/121 | § Result has improved § Revenue from Operations came at Rs. 951.8 Cr (11.3% QoQ, -10% YoY) vs QoQ Rs. 855.4 Cr, YoY Rs. 1057.3 Cr § EBIDTA came at Rs. 400.6 Cr (19.4% QoQ, -4.6% YoY) vs QoQ Rs. 335.6 Cr, YoY Rs. 420 Cr § EBITDA Margin came at 42.1% vs QoQ 39.2%, YoY 39.7% § Adj. PAT came at Rs. 452.3 Cr vs QoQ Rs. 266.1 Cr, YoY Rs. 177 Cr § Quarter EPS is Rs. 14.2 § Stock is trading at P/E of 4.3x TTM EPS |
Apex Frozen Foods Ltd. | CMP Rs. 206 | M Cap Rs. 644 Cr | 52 W H/L 365/184 | § Result has declined § Revenue from Operations came at Rs. 211.9 Cr (-8.1% QoQ, 1.2% YoY) vs QoQ Rs. 230.5 Cr, YoY Rs. 209.2 Cr § EBIDTA came at Rs. 7.6 Cr (-58.6% QoQ, -58.4% YoY) vs QoQ Rs. 18.4 Cr, YoY Rs. 18.4 Cr § EBITDA Margin came at 3.6% vs QoQ 8%, YoY 8.8% § Adj. PAT came at Rs. -4 Cr vs QoQ Rs. 7.7 Cr, YoY Rs. 7.3 Cr § Quarter EPS is Rs. -1.3 § Stock is trading at P/E of 17.9x TTM EPS |
Jindal Poly Films Ltd. | CMP Rs. 662 | M Cap Rs. 2899 Cr | 52 W H/L 1187/485 | § Result has declined § Revenue from Operations came at Rs. 734 Cr (-17.2% QoQ, -57.3% YoY) vs QoQ Rs. 886.7 Cr, YoY Rs. 1720.9 Cr § EBIDTA came at Rs. 11.6 Cr (-114.2% QoQ, -97.4% YoY) vs QoQ Rs. -81.4 Cr, YoY Rs. 452.5 Cr § EBITDA Margin came at 1.6% vs QoQ -9.2%, YoY 26.3% § Adj. PAT came at Rs. -385 Cr vs QoQ Rs. -96.6 Cr, YoY Rs. 421.9 Cr § Quarter EPS is Rs. -87.9 § Stock is trading at P/E of 9.1x TTM EPS |
For feedback/clarifications, simply drop us a mail at equityr...@nirmalbang.com
Warm Regards,
Retail Research